HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
复制标题
DOI：
10.1371/journal.pone.0161219
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Chen B
中科院分区：
文献类型：
--
作者：
Cao GD;Chen K;Xiong MM;Chen B
人表皮生长因子受体(HER)家族在胃癌，尤其是HER2中起重要作用。HER2受到了太多的关注，然而，HER3和HER4过表达在胃癌中的作用往往被忽视。HER3和HER4在胃癌中的临床病理和预后作用存在争议。在这项研究中，系统回顾和荟萃分析评估HER3或HER4作为预测胃癌患者临床病理和生存时间的指标。通过多种搜索策略在PubMed、Ovid、Web of Science和Cochrane数据库上搜索符合条件的研究。采用Revman 5.3软件进行数据收集和统计分析。采用纽卡斯尔-渥太华量表评估纳入研究的质量。共检索到448篇关于HER3过表达与GC的研究，398篇关于HER4过表达与GC的研究。在这些研究中，5篇关于HER3的合格研究(包括1016名胃癌患者)和3篇关于HER4的合格研究(包括793名GC患者)符合纳入标准。结果显示，HER3、HER4过表达与肿瘤侵袭深度(OR=0.44，95%CI0.29~0.67，P=0.0002和OR=0.50，95%CI0.38~0.86，P=0.007)、淋巴结转移(OR=0.40，95%CI0.20~0.77，P=0.007和OR=0.57，95%CI0.38~0.86，P=0.007)有关；HER3过表达提示肿瘤转移(TNM)分期较晚(OR=0.50，95%CI为0.22~1.15，P=0.10)，预后较差(RR=0.71，95%CI为0.61~0.84，P<；而HER4过表达与肿瘤的临床分期(OR=0.00001.6 0，95%CI 0.2 0~1.78)和生存期(RR=1.0 9，95%CI 0.91~1.3 0)无关。这一荟萃分析表明，HER3在胃癌的临床病理和预后中起着重要作用。然而，HER4可能不是预测胃癌预后的理想因素。
Human epidermal growth factor receptor (HER) family plays an important role in gastric cancer (GC), especially HER2. Too much attention has been paid to HER2; however, the functions of HER3 and HER4 overexpression in GC are always ignored. The clinicopathological and prognostic roles of HER3 and HER4 in GC are controversial. In this study, a systematic review and meta-analysis was conducted to evaluate the use of HER3 or HER4 as a predictor of clinicopathology and survival time in GC patients. Eligible studies were searched on PubMed, Ovid, Web of Science, and Cochrane databases through multiple search strategies. Data collection and statistical analysis were carried out by the Revman 5.3 software. The Newcastle-Ottawa scale was used to assess the quality of included studies. A total of 448 studies about HER3 overexpression and GC, and 398 studies about HER4 overexpression and GC were searched. Of these, 5 eligible studies about HER3 including 1016 GC patients and 3 eligible studies about HER4 including 793 GC patients met the inclusion criteria. The results showed that HER3 and HER4 overexpression were significantly associated with depth of tumor invasion (OR = 0.44, 95%CI 0.29–0.67, P = 0.0002 and OR = 0.50, 95%CI 0.38–0.86, P = 0.007) and lymph node metastasis (OR = 0.40, 95%CI 0.20–0.77, P = 0.007 and OR = 0.57, 95%CI 0.38–0.86, P = 0.007), and HER3 overexpression reveals a tendency of later tumor node metastases (TNM) stage (OR = 0.50, 95%CI 0.22–1.15, P = 0.10) and predicts a worse survival time (RR = 0.71, 95%CI 0.61–0.84, P<0.00001), while HER4 overexpression had no correlation with TNM stage (OR = 0.60, 95%CI 0.20–1.78) and survival time (RR = 1.09, 95%CI 0.91–1.30). This meta-analysis indicated that HER3 plays an essential role in the clinicopathology and prognosis of GC. However, HER4 may not be an ideal prognostic factor for GC.